Literature DB >> 22001455

Transient myoclonic state with asterixis: primary motor cortex hyperexcitability is correlated with myoclonus.

Takefumi Hitomi1, Akio Ikeda, Morito Inouchi, Hisaji Imamura, Tomokazu Nakagawa, Tomoyuki Fumuro, Riki Matsumoto, Ryosuke Takahashi.   

Abstract

OBJECTIVE: To clarify the clinical features and mechanism of the transience of myoclonus in patients with a transient myoclonic state with asterixis (TMA).
METHODS: We investigated the clinical and eletrophysiological profiles of 6 patients with TMA (age: 84±3 years). During an asymptomatic period, somatosensory evoked potentials (SEPs) were recorded in all 6 patients and motor evoked potentials (MEPs) were examined in 1 patient. SEPs were recorded and jerk-locked back averaging (JLA) was performed in 2 patients while symptomatic. SEPs were also recorded from 8 aged control subjects (age: 68±5 years).
RESULTS: All TMA patients had mild chronic systemic diseases. During an asymptomatic period, SEP amplitudes were not significantly enlarged in comparison with control subjects, and MEPs were normal. Examination of 2 patients during symptomatic period indicated no enlargement of SEP amplitudes and JLA disclosed a positive spike preceding myoclonic jerks. In one of these patients, the amplitude of the positive spike decreased once myoclonus improved.
CONCLUSION: TMA occurred in aged patients with mild chronic systemic diseases. JLA findings and the absence of giant SEPs further support that TMA is a cortical non-reflex myoclonus. In addition, transient hyperexcitability at the primary motor cortex disclosed by JLA correlated well with its transient symptoms.

Entities:  

Mesh:

Year:  2011        PMID: 22001455     DOI: 10.2169/internalmedicine.50.5590

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  1 in total

1.  Late relapse myoclonus in a case of Lance-Adams syndrome.

Authors:  Tjerk Lagrand; Ania Winogrodzka
Journal:  BMJ Case Rep       Date:  2013-11-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.